Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.

被引：4
|
作者：
Wang-Gillam, Andrea
Hubner, Richard
Mirakhur, Beloo
de Jong, Floris A.
Belanger, Bruce
Chen, Li-Tzong
机构：
[1] Washington Univ, Sch Med St Louis, St Louis, MO USA
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[4] Shire GmbH, Zug, Switzerland
[5] Ipsen Biosci Inc, Cambridge, MA USA
[6] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.388
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
    Chen, L-T.
    Macarulla, T. M.
    Blanc, J.
    Mirakhur, B.
    de Jong, F. A.
    Belanger, B.
    Bekaii-Saab, T.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 250 - U388
  • [2] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Yanshen, Shan
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Belanger, B.
    Bayever, E.
    de Jong, F.
    von Hoff, D. D.
    Siveke, J. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 6 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Shan, Y-S.
    Mercade, T. Macarulla
    Blanc, J. F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Siveke, J.
    Belanger, B.
    de Jong, F.
    Mamlouk, K.
    von Hoff, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L. -T.
    Siveke, J.
    Wang-Gillam, A.
    Hubner, R.
    Pant, S.
    Dragovich, T.
    Chung, V.
    Chang, D.
    Ross, P.
    Cooray, P.
    Tebbutt, N.
    Franke, F.
    Belanger, B.
    Dhindsa, N.
    de Jong, F.
    Mamlouk, K.
    Von Hoff, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 110 - 110
  • [7] Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
    Chen, Li-Tzong
    Siveke, Jens T.
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew P.
    Shan, Yan-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Mamlouk, Khalid
    Belanger, Bruce
    de Jong, Floris A.
    Hubner, Richard A.
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 71 - 78
  • [8] A phase 1/2, open -label, dose -expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
    Wainberg, Z.
    Boland, P.
    Lieu, C.
    Dayyani, F.
    Macarulla, T.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Wang, T.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
    Ioka, T.
    Nakamori, S.
    Sugimori, K.
    Kanai, M.
    Ikeda, M.
    Ozaka, M.
    Furukawa, M.
    Okusaka, T.
    Kawabe, K.
    Furuse, J.
    Komatsu, Y.
    Sato, A.
    Shimizu, S.
    Chugh, P.
    Tang, R.
    Ueno, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345